tradingkey.logo

Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks

ReutersFeb 2, 2026 12:24 PM

- Sagimet Biosciences Inc SGMT.O:

  • SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) TABLETS IN PATIENTS WITH MODERATE TO SEVERE ACNE

  • SAGIMET BIOSCIENCES INC - DENIFANSTAT WELL TOLERATED WITH TEAES INCIDENCE RATE OF 5% OR MORE

  • SAGIMET BIOSCIENCES INC - DENIFANSTAT SHOWS IMPROVEMENTS IN EFFICACY ENDPOINTS BEYOND 12 WEEKS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI